{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:23:39Z","timestamp":1792657419819,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1111\/ajt.17009","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T16:10:34Z","timestamp":1645805434000},"page":"1646-1657","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2402-7764","authenticated-orcid":false,"given":"Hartmut H.","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Wixner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violaine","family":"Plant\u00e9-Bordeneuve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Mu\u00f1oz-Beamud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3717-3306","authenticated-orcid":false,"given":"Laura","family":"Llad\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian D.","family":"Gillmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1914-6184","authenticated-orcid":false,"given":"Anna","family":"Mazzeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Arum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Y.","family":"Jay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1111\/ajt.17009_bib1","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1212\/WNL.0000000000001870","article-title":"Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study","volume":"85","author":"Adams","year":"2015","journal-title":"Neurology."},{"issue":"1","key":"10.1111\/ajt.17009_bib2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11897-013-0182-4","article-title":"Novel drugs targeting transthyretin amyloidosis","volume":"11","author":"Hanna","year":"2014","journal-title":"Curr Heart Fail Rep."},{"issue":"10","key":"10.1111\/ajt.17009_bib3","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.acvd.2013.06.051","article-title":"Cardiac amyloidosis: updates in diagnosis and management","volume":"106","author":"Mohty","year":"2013","journal-title":"Arch Cardiovasc Dis."},{"issue":"1","key":"10.1111\/ajt.17009_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1111\/ajt.17009_bib5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1111\/ajt.17009_bib6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1185\/03007995.2012.754348","article-title":"THAOS \u2013 The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis","volume":"29","author":"Coelho","year":"2013","journal-title":"Curr Med Res Opin."},{"issue":"1","key":"10.1111\/ajt.17009_bib7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jns.12153","article-title":"\u201cRed-flag\u201d symptom clusters in transthyretin familial amyloid polyneuropathy","volume":"21","author":"Concei\u00e7\u00e3o","year":"2016","journal-title":"J Peripher Nerv Syst."},{"issue":"7","key":"10.1111\/ajt.17009_bib8","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","article-title":"Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective","volume":"34","author":"Rapezzi","year":"2013","journal-title":"Eur Heart J."},{"issue":"6","key":"10.1111\/ajt.17009_bib9","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/msj.21352","article-title":"Amyloid neuropathies","volume":"79","author":"Shin","year":"2012","journal-title":"Mt Sinai J Med."},{"issue":"8","key":"10.1111\/ajt.17009_bib10","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3109\/07853890.2015.1068949","article-title":"Evolving landscape in the management of transthyretin amyloidosis","volume":"47","author":"Hawkins","year":"2015","journal-title":"Ann Med."},{"issue":"1","key":"10.1111\/ajt.17009_bib11","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s13023-020-01575-6","article-title":"Patient-reported outcomes on familial amyloid polyneuropathy (FAP)","volume":"15","author":"Bolte","year":"2020","journal-title":"Orphanet J Rare Dis."},{"issue":"5","key":"10.1111\/ajt.17009_bib12","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0025-6196(12)60388-7","article-title":"Familial amyloidosis: a study of 52 North American-born patients examined during a 30-year period","volume":"67","author":"Gertz","year":"1992","journal-title":"Mayo Clin Proc."},{"issue":"9","key":"10.1111\/ajt.17009_bib13","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/eurheartj\/ehr383","article-title":"Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant","volume":"33","author":"Sattianayagam","year":"2012","journal-title":"Eur Heart J."},{"issue":"2","key":"10.1111\/ajt.17009_bib14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/13506129.2015.1019610","article-title":"Hereditary ATTR amyloidosis: a single-institution experience with 266 patients","volume":"22","author":"Swiecicki","year":"2015","journal-title":"Amyloid."},{"issue":"9","key":"10.1111\/ajt.17009_bib15","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","article-title":"Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative?","volume":"99","author":"Ericzon","year":"2015","journal-title":"Transplantation."},{"issue":"3","key":"10.1111\/ajt.17009_bib16","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1399-0004.1991.tb03085.x","article-title":"Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30)","volume":"40","author":"Holmgren","year":"1991","journal-title":"Clin Genet."},{"key":"10.1111\/ajt.17009_bib17","unstructured":"FAPWTR Results from the Familial World Transplant Registry. http:\/\/www.FAPWTR.org. Published 2018. Accessed December 22, 2021."},{"issue":"Pt 7","key":"10.1111\/ajt.17009_bib18","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/brain\/123.7.1495","article-title":"The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation","volume":"123","author":"Adams","year":"2000","journal-title":"Brain."},{"issue":"3","key":"10.1111\/ajt.17009_bib19","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/lt.24058","article-title":"Liver transplantation in transthyretin amyloidosis: issues and challenges","volume":"21","author":"Carvalho","year":"2015","journal-title":"Liver Transpl."},{"issue":"10","key":"10.1111\/ajt.17009_bib20","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/lt.21817","article-title":"Liver transplantation for familial amyloidotic polyneuropathy: impact on Swedish patients\u2019 survival","volume":"15","author":"Okamoto","year":"2009","journal-title":"Liver Transpl."},{"key":"10.1111\/ajt.17009_bib21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"8","author":"Ando","year":"2013","journal-title":"Orphanet J Rare Dis."},{"issue":"21","key":"10.1111\/ajt.17009_bib22","doi-asserted-by":"crossref","first-page":"e1999","DOI":"10.1212\/WNL.0000000000006543","article-title":"Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy","volume":"91","author":"Coelho","year":"2018","journal-title":"Neurology."},{"issue":"4","key":"10.1111\/ajt.17009_bib23","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/joim.12585","article-title":"One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition","volume":"281","author":"Suhr","year":"2017","journal-title":"J Intern Med."},{"issue":"5","key":"10.1111\/ajt.17009_bib24","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/00007890-200203150-00015","article-title":"Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type","volume":"73","author":"Olofsson","year":"2002","journal-title":"Transplantation."},{"issue":"11","key":"10.1111\/ajt.17009_bib25","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1111\/j.1600-6143.2007.01969.x","article-title":"Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years","volume":"7","author":"Yamamoto","year":"2007","journal-title":"Am J Transplant."},{"issue":"4","key":"10.1111\/ajt.17009_bib26","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1212\/WNL.0b013e3181ea15d4","article-title":"Progression of transthyretin amyloid neuropathy after liver transplantation","volume":"75","author":"Liepnieks","year":"2010","journal-title":"Neurology."},{"issue":"3","key":"10.1111\/ajt.17009_bib27","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1006\/bbrc.2000.3203","article-title":"Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin","volume":"274","author":"Yazaki","year":"2000","journal-title":"Biochem Biophys Res Commun."},{"issue":"3","key":"10.1111\/ajt.17009_bib28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/13506120903090726","article-title":"Quality of life in patients with familial amyloidotic polyneuropathy long-term after liver transplantation","volume":"16","author":"Drent","year":"2009","journal-title":"Amyloid."},{"issue":"Suppl. 1 47","key":"10.1111\/ajt.17009_bib29","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00003643-201006121-00040","article-title":"Comparison of outcome data after liver transplant: familial amyloid polyneuropathy (Portuguese type) recipients versus classical indications for liver transplant [abstract]","volume":"27","author":"Sa Couto","year":"2010","journal-title":"Eur J Anaesthesiol."},{"issue":"11","key":"10.1111\/ajt.17009_bib30","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2169\/internalmedicine.44.1151","article-title":"Ten years of experience with liver transplantation for familial amyloid polyneuropathy in Japan: outcomes of living donor liver transplantations","volume":"44","author":"Takei","year":"2005","journal-title":"Intern Med."},{"issue":"3","key":"10.1111\/ajt.17009_bib31","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/lt.21996","article-title":"Liver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: a single-center experience","volume":"16","author":"Barreiros","year":"2010","journal-title":"Liver Transpl."},{"issue":"19","key":"10.1111\/ajt.17009_bib32","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1016\/j.jacc.2015.08.870","article-title":"Prediction of long-term survival after liver transplantation for familial transthyretin amyloidosis","volume":"66","author":"Algalarrondo","year":"2015","journal-title":"J Am Coll Cardiol."},{"issue":"4","key":"10.1111\/ajt.17009_bib33","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/13506129.2018.1550061","article-title":"Cause of death analysis and temporal trends in survival after liver transplantation for transthyretin familial amyloid polyneuropathy","volume":"25","author":"Algalarrondo","year":"2018","journal-title":"Amyloid."},{"issue":"7","key":"10.1111\/ajt.17009_bib34","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","article-title":"Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease","volume":"15","author":"Adams","year":"2019","journal-title":"Nat Rev Neurol."},{"issue":"1","key":"10.1111\/ajt.17009_bib35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/jcph.1480","article-title":"Patisiran pharmacokinetics, pharmacodynamics, and exposure-response analyses in the phase 3 APOLLO trial in patients with hereditary transthyretin-mediated (hATTR) amyloidosis","volume":"60","author":"Zhang","year":"2020","journal-title":"J Clin Pharmacol."},{"key":"10.1111\/ajt.17009_bib36","doi-asserted-by":"crossref","first-page":"116424","DOI":"10.1016\/j.jns.2019.116424","article-title":"Development of measures of polyneuropathy impairment in hATTR amyloidosis: from NIS to mNIS+7","volume":"405","author":"Dyck","year":"2019","journal-title":"J Neurol Sci."},{"issue":"2","key":"10.1111\/ajt.17009_bib37","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/jns5.12059","article-title":"Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy","volume":"19","author":"Vinik","year":"2014","journal-title":"J Peripher Nerv Syst."},{"issue":"4","key":"10.1111\/ajt.17009_bib38","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1212\/WNL.0b013e318208824b","article-title":"Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies","volume":"76","author":"van Nes","year":"2011","journal-title":"Neurology."},{"issue":"12","key":"10.1111\/ajt.17009_bib39","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.mayocp.2012.10.013","article-title":"COMPASS 31: a refined and abbreviated Composite Autonomic Symptom Score","volume":"87","author":"Sletten","year":"2012","journal-title":"Mayo Clin Proc."},{"issue":"4","key":"10.1111\/ajt.17009_bib40","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/009286150804200402","article-title":"Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials","volume":"42","author":"Mallinckrodt","year":"2008","journal-title":"Drug Info J."},{"issue":"1","key":"10.1111\/ajt.17009_bib41","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1474-4422(20)30368-9","article-title":"Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study","volume":"20","author":"Adams","year":"2021","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1111\/ajt.17009_bib42","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/13506129.2020.1730790","article-title":"Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis","volume":"27","author":"Obici","year":"2020","journal-title":"Amyloid."},{"key":"10.1111\/ajt.17009_bib43","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1750-1172-9-61","article-title":"THAOS: gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease","volume":"9","author":"Wixner","year":"2014","journal-title":"Orphanet J Rare Dis."},{"issue":"1","key":"10.1111\/ajt.17009_bib44","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13023-020-01399-4","article-title":"A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis","volume":"15","author":"Coelho","year":"2020","journal-title":"Orphanet J Rare Dis."},{"issue":"4","key":"10.1111\/ajt.17009_bib45","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/13506120701614032","article-title":"Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation","volume":"14","author":"Liepnieks","year":"2007","journal-title":"Amyloid."},{"issue":"4","key":"10.1111\/ajt.17009_bib46","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1080\/13506129.2020.1784134","article-title":"TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patients","volume":"27","author":"Moshe-Lilie","year":"2020","journal-title":"Amyloid."},{"key":"10.1111\/ajt.17009_bib47","unstructured":"Akcea Therapeutics US prescribing information: TEGSEDI (inotersen) injection, for subcutaneous use \u2013 October 2019 update. https:\/\/tegsedi.com\/prescribing-information.pdf. Published 2019. Accessed December 22, 2021."},{"key":"10.1111\/ajt.17009_bib48","unstructured":"European Medicines Agency Summary of product characteristics: Tegsedi 284 mg solution for injection in pre-filled syringe 2019. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tegsedi-epar-product-information_en.pdf. Accessed December 22, 2021."},{"issue":"4","key":"10.1111\/ajt.17009_bib49","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3988\/jcn.2017.13.4.444","article-title":"Tafamidis for a transplant patient with transthyretin amyloid polyneuropathy","volume":"13","author":"Romero-Imbroda","year":"2017","journal-title":"J Clin Neurol."},{"key":"10.1111\/ajt.17009_bib50","unstructured":"European Medicines Agency Summary of product characteristics: Vyndaqel 20 mg soft capsules. emc: DataPharm. https:\/\/www.medicines.org.uk\/emc\/product\/2837\/smpc. Published 2020. Accessed December 22, 2021."}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajt.17009","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajt.17009","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522082466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522082466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajt.17009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:37:33Z","timestamp":1761629853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522082466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1600613522082466"],"URL":"https:\/\/doi.org\/10.1111\/ajt.17009","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/ajt.17009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}